Otonomy Announces Plan to Focus Resources on Development Programs

Back to Jobs

Company to focus resources on completing OTIVIDEX™  clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and tinnitus Discontinuing commercial support of OTIPRIO ® which is expected to save more than $20

Apply Now